Logo image of GLPG

GALAPAGOS NV-SPON ADR (GLPG) Stock Fundamental Analysis

NASDAQ:GLPG - Nasdaq - US36315X1019 - ADR - Currency: USD

33.11  -0.16 (-0.48%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to GLPG. GLPG was compared to 553 industry peers in the Biotechnology industry. GLPG scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. GLPG does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year GLPG has reported negative net income.
In the past year GLPG has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: GLPG reported negative net income in multiple years.
In the past 5 years GLPG always reported negative operating cash flow.
GLPG Yearly Net Income VS EBIT VS OCF VS FCFGLPG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B

1.2 Ratios

With an excellent Return On Assets value of -7.45%, GLPG belongs to the best of the industry, outperforming 85.71% of the companies in the same industry.
Looking at the Return On Equity, with a value of -10.75%, GLPG belongs to the top of the industry, outperforming 88.07% of the companies in the same industry.
Industry RankSector Rank
ROA -7.45%
ROE -10.75%
ROIC N/A
ROA(3y)0.68%
ROA(5y)-1.06%
ROE(3y)0.5%
ROE(5y)-2.77%
ROIC(3y)N/A
ROIC(5y)N/A
GLPG Yearly ROA, ROE, ROICGLPG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10 -20 -30

1.3 Margins

GLPG's Profit Margin has improved in the last couple of years.
GLPG has a Gross Margin of 87.59%. This is amongst the best in the industry. GLPG outperforms 90.96% of its industry peers.
In the last couple of years the Gross Margin of GLPG has declined.
The Profit Margin and Operating Margin are not available for GLPG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 87.59%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y9.7%
GM growth 3Y-4.31%
GM growth 5YN/A
GLPG Yearly Profit, Operating, Gross MarginsGLPG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100

More info and screens

4

2. Health

2.1 Basic Checks

GLPG does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GLPG remains at a similar level compared to 1 year ago.
GLPG has more shares outstanding than it did 5 years ago.
GLPG has a worse debt/assets ratio than last year.
GLPG Yearly Shares OutstandingGLPG Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
GLPG Yearly Total Debt VS Total AssetsGLPG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

Based on the Altman-Z score of 1.51, we must say that GLPG is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of GLPG (1.51) is better than 68.17% of its industry peers.
GLPG has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
GLPG has a Debt to Equity ratio (0.00) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.51
ROIC/WACCN/A
WACC7.72%
GLPG Yearly LT Debt VS Equity VS FCFGLPG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B

2.3 Liquidity

A Current Ratio of 8.08 indicates that GLPG has no problem at all paying its short term obligations.
With a decent Current ratio value of 8.08, GLPG is doing good in the industry, outperforming 70.89% of the companies in the same industry.
A Quick Ratio of 7.99 indicates that GLPG has no problem at all paying its short term obligations.
GLPG has a better Quick ratio (7.99) than 70.34% of its industry peers.
Industry RankSector Rank
Current Ratio 8.08
Quick Ratio 7.99
GLPG Yearly Current Assets VS Current LiabilitesGLPG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

More info and screens

1

3. Growth

3.1 Past

The earnings per share for GLPG have decreased strongly by -200.70% in the last year.
GLPG shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -12.47% yearly.
Looking at the last year, GLPG shows a very negative growth in Revenue. The Revenue has decreased by -52.50% in the last year.
GLPG shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -20.82% yearly.
EPS 1Y (TTM)-200.7%
EPS 3YN/A
EPS 5Y-12.47%
EPS Q2Q%-1242.86%
Revenue 1Y (TTM)-52.5%
Revenue growth 3Y-20.01%
Revenue growth 5Y-20.82%
Sales Q2Q%-16.16%

3.2 Future

GLPG is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -40.74% yearly.
GLPG is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -1.15% yearly.
EPS Next Y-198.38%
EPS Next 2Y-80.47%
EPS Next 3Y-70.29%
EPS Next 5Y-40.74%
Revenue Next Year-7.45%
Revenue Next 2Y-3.94%
Revenue Next 3Y-4.29%
Revenue Next 5Y-1.15%

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
GLPG Yearly Revenue VS EstimatesGLPG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M
GLPG Yearly EPS VS EstimatesGLPG Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GLPG. In the last year negative earnings were reported.
Also next year GLPG is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GLPG Price Earnings VS Forward Price EarningsGLPG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GLPG Per share dataGLPG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40

4.3 Compensation for Growth

GLPG's earnings are expected to decrease with -70.29% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-80.47%
EPS Next 3Y-70.29%

More info and screens

0

5. Dividend

5.1 Amount

GLPG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GALAPAGOS NV-SPON ADR

NASDAQ:GLPG (7/31/2025, 12:55:59 PM)

33.11

-0.16 (-0.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-23 2025-07-23/amc
Earnings (Next)10-22 2025-10-22
Inst Owners49.75%
Inst Owner Change0%
Ins Owners0%
Ins Owner ChangeN/A
Market Cap2.18B
Analysts50.59
Price Target34.66 (4.68%)
Short Float %3.27%
Short Ratio5.19
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1378.49%
Min EPS beat(2)-1682.53%
Max EPS beat(2)-1074.45%
EPS beat(4)1
Avg EPS beat(4)-663.96%
Min EPS beat(4)-1682.53%
Max EPS beat(4)154.1%
EPS beat(8)5
Avg EPS beat(8)-142.38%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-2.96%
Min Revenue beat(2)-10.27%
Max Revenue beat(2)4.35%
Revenue beat(4)1
Avg Revenue beat(4)-8.31%
Min Revenue beat(4)-15.5%
Max Revenue beat(4)4.35%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.3%
PT rev (3m)-1.6%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.31%
EPS NY rev (3m)-0.29%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.72%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.87
P/FCF N/A
P/OCF N/A
P/B 0.72
P/tB 0.78
EV/EBITDA N/A
EPS(TTM)-4.99
EYN/A
EPS(NY)-1.63
Fwd EYN/A
FCF(TTM)-5.21
FCFYN/A
OCF(TTM)-4.87
OCFYN/A
SpS4.82
BVpS46.25
TBVpS42.46
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7.45%
ROE -10.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 87.59%
FCFM N/A
ROA(3y)0.68%
ROA(5y)-1.06%
ROE(3y)0.5%
ROE(5y)-2.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y9.7%
GM growth 3Y-4.31%
GM growth 5YN/A
F-Score1
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 30.4%
Cap/Sales 7.05%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.08
Quick Ratio 7.99
Altman-Z 1.51
F-Score1
WACC7.72%
ROIC/WACCN/A
Cap/Depr(3y)93.66%
Cap/Depr(5y)187.37%
Cap/Sales(3y)17.05%
Cap/Sales(5y)15.82%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-200.7%
EPS 3YN/A
EPS 5Y-12.47%
EPS Q2Q%-1242.86%
EPS Next Y-198.38%
EPS Next 2Y-80.47%
EPS Next 3Y-70.29%
EPS Next 5Y-40.74%
Revenue 1Y (TTM)-52.5%
Revenue growth 3Y-20.01%
Revenue growth 5Y-20.82%
Sales Q2Q%-16.16%
Revenue Next Year-7.45%
Revenue Next 2Y-3.94%
Revenue Next 3Y-4.29%
Revenue Next 5Y-1.15%
EBIT growth 1Y-98.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-27.31%
EBIT Next 3Y-19.94%
EBIT Next 5Y20.96%
FCF growth 1Y45.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y46.13%
OCF growth 3YN/A
OCF growth 5YN/A